Folio · SPXSet Report · Digest
v0.7.0 STABLE · 2026-11-11 · r4

2026-W46 · Nov 9–Nov 15 · Company · Profile · published

Index >>> Company >>> Profile

Pfizer Inc. (PFE) — XLV Health Care · S&P 500 Profile |輝瑞介紹

health-careS&P500xlvxlv-top-25
SPXSet Studio
IN-HOUSE RESEARCH · 站內獨立研究

Pfizer Inc. (PFE) — Business, History & S&P 500 Profile | 輝瑞

Pfizer Inc. company profile · business segments · history · financial snapshot · S&P 500 rank #73 · 輝瑞公司業務歷史財務與標普500地位

中文版 ↓

PROFILE
Market data as of Oct 29, 2026 (ET) close
Financials: FY2024
MARKET CAP
$170.71B
Oct 29, 2026 close
S&P 500 WEIGHT
0.24%
Rank #73 · Oct 29, 2026
SECTOR RANK
#10
Health Care · Oct 29, 2026
S&P 500 RANK
#73
0.24% · Oct 29, 2026

SNAPSHOT

TickerPFE
CompanyPfizer Inc.
GICS sector / industryHealth Care (XLV) / Pharmaceuticals
S&P 500 rank (by weight)#73 · 0.24% (Oct 29, 2026)
Sector rank#10 in Health Care (Oct 29, 2026)
HeadquartersNew York, New York
Founded1849
CEOAlbert Bourla
EmployeesApproximately 81,000 (FY2024)
Market cap$170.71B (Oct 30, 2026)
Share price$30.52 (Oct 30, 2026 close)
SEC filingsEDGAR — CIK 0000078003

WHAT IT DOES

Pfizer researches, develops and sells prescription medicines and vaccines worldwide.

Its portfolio spans primary care, specialty care and oncology, with Eliquis, Prevnar and Comirnaty among the largest products.

The company reports a single Biopharma segment; the table above groups products for readability.

BUSINESS SEGMENTS

Primary CareMedicines for common conditions, including vaccines and antivirals.
Specialty CareMedicines for rare and complex conditions.
OncologyCancer medicines and therapies.
Pfizer reports a single Biopharma segment; the rows above are product groups, not reportable segments.

HISTORY

YearMilestone
1849Charles Pfizer and Charles Erhart found Pfizer in Brooklyn, New York.
1998Pfizer launches Viagra.
2009Pfizer acquires Wyeth.
2020Pfizer and BioNTech co-develop Comirnaty, the first authorized COVID-19 vaccine.

COMPETITIVE POSITION

  • Comirnaty COVID-19 vaccine
  • Paxlovid antiviral
  • Eliquis anticoagulant
  • Prevnar pneumococcal vaccines
  • Ibrance cancer therapy

FINANCIAL SNAPSHOT

Total revenue$62.58B (FY2025 revenues)
Operating incomeNot available
Net income$7.77B (FY2025 net income attributable to Pfizer Inc.)
Diluted EPS$1.36 (FY2025 diluted EPS)
Source: Pfizer Inc. Form 10-K for the year ended December 31, 2025 (revenues $62.58B; net income attributable to Pfizer Inc. $7.77B; diluted EPS $1.36). Operating income was not stated as a clean single line in the sources consulted and is shown as Not available.

KEY RISKS

  • Patent expirations, including Eliquis and the post-COVID product cliff, pressure revenue.
  • Drug pricing politics and negotiation programs can compress margins.
  • R&D outcomes are binary: a failed pivotal trial can erase years of investment.
  • M&A integration, including the Seagen acquisition, must deliver promised synergies.
  • Litigation and product-liability exposure persist across the portfolio.

WHY IT MATTERS FOR THE S&P 500

Pfizer is a scale pharmaceutical company in transition: COVID-era revenues are fading, and the investment case rests on the oncology pipeline from Seagen and new launches replacing expiring blockbusters. The risk is the patent cliff arriving faster than the pipeline.

SOURCES & METHODOLOGY

Financials, segments, headquartersPfizer Inc. Form 10-K for the year ended December 31, 2024 (revenues $62.66B; net income attributable to Pfizer Inc. $8.03B; diluted EPS $1.41). Operating income was not stated as a clean single line in the sources consulted and is shown as Not available.
Index weight & ranksSlickcharts S&P 500 weights, Oct 29, 2026 close, fetched Oct 30, 2026
Market cap$170.71B (Oct 30, 2026)
LogoSPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics.

FINANCIALS

繁體中文版

公司快照

股票代號PFE
公司輝瑞公司
GICS 板塊/行業健康護理(XLV)/製藥
標普500排名(按權重)#73 · 0.24%(Oct 29, 2026)
板塊內排名健康護理 #10(Oct 29, 2026)
總部紐約州紐約市
成立1849 年
執行長艾伯樂
員工約 81,000 人(2024 年)
市值$170.71B(Oct 30, 2026)
股價$30.52(Oct 30, 2026 收盤)
SEC 申報EDGAR — CIK 0000078003

業務概覽

輝瑞在全球研發、開發及銷售處方藥與疫苗。

其組合涵蓋基層醫療、專科醫療與腫瘤學,Eliquis、Prevnar 與 Comirnaty 為最大的產品。

公司按單一生物製藥分部報告;上表按產品群組整理以便閱讀。

業務板塊

基層醫療常見疾病藥物,包括疫苗與抗病毒藥。
專科醫療罕見與複雜疾病藥物。
腫瘤學癌症藥物與療法。
輝瑞按單一生物製藥分部報告;上表為產品群組,非獨立報告分部。

歷史沿革

年份里程碑
1849 年查爾斯·輝瑞與查爾斯·厄哈特在紐約布魯克林創立輝瑞。
1998 年輝瑞推出威而鋼。
2009 年輝瑞收購惠氏。
2020 年輝瑞與 BioNTech 共同開發 Comirnaty——首款獲授權的新冠疫苗。

競爭地位

  • Comirnaty 新冠疫苗
  • Paxlovid 抗病毒藥
  • Eliquis 抗凝血藥
  • Prevnar 肺炎球菌疫苗
  • Ibrance 癌症療法

財務快照

總收入$62.58B(FY2025 收入)
營業利潤暫無資料
淨利潤$7.77B(FY2025 歸屬於輝瑞的淨利潤)
稀釋 EPS$1.36(FY2025 攤薄每股收益)
來源:輝瑞截至 2025 年 12 月 31 日年度之 Form 10-K(收入 625.8 億美元;歸屬於輝瑞的淨利潤 77.7 億美元;攤薄每股收益 1.36 美元)。所查來源未以清晰單列呈現營業收入,故以「未提供」表示。

主要風險

  • 專利到期(包括 Eliquis 與後新冠產品懸崖)對收入構成壓力。
  • 藥價政治與談判計劃可能壓縮利潤。
  • 研發結果具二元性:關鍵試驗失敗可能抹去多年投資。
  • 併購整合(包括 Seagen 收購)必須兌現承諾的協同效應。
  • 訴訟與產品責任風險持續存在於整個組合。

對標普500的重要性

輝瑞是處於轉型期的規模製藥公司:新冠時代收入正在消退,投資論點取決於 Seagen 帶來的腫瘤學管線與新品能否替代到期的大藥。風險在於專利懸崖來得比管線更快。

來源與方法

財務、板塊、總部輝瑞截至 2024 年 12 月 31 日年度之 Form 10-K(收入 626.6 億美元;歸屬於輝瑞的淨利潤 80.3 億美元;攤薄每股收益 1.41 美元)。所查來源未以清晰單列呈現營業收入,故以「未提供」表示。
指數權重與排名Slickcharts S&P 500 權重,Oct 29, 2026 收盤,Oct 30, 2026 抓取
市值$170.71B(Oct 30, 2026)
LogoSPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。

財報

SPXSet Studio

SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。

SPXSet · Company Library · PFE
Data as of Oct 29, 2026 · Financials FY2024 (10-K) · Market data Oct 2026
Previous · Welltower Inc. (WELL) — XLRE Real Estate · S&P 500 Profile |Welltower介紹Next · NextEra Energy, Inc. (NEE) — XLU Utilities · S&P 500 Profile |新紀元能源介紹

Entered 2026-10-30 05:23 · updated 2026-11-14 23:55 · rev 8